0000950170-24-016667.txt : 20240216 0000950170-24-016667.hdr.sgml : 20240216 20240216203246 ACCESSION NUMBER: 0000950170-24-016667 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PATTERSON LEONE D CENTRAL INDEX KEY: 0001233539 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40656 FILM NUMBER: 24650343 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tenaya Therapeutics, Inc. CENTRAL INDEX KEY: 0001858848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813789973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD., SUITE 500 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-865-2066 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD., SUITE 500 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-02-16 false 0001858848 Tenaya Therapeutics, Inc. TNYA 0001233539 PATTERSON LEONE D C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLOOR SOUTH SAN FRANCISCO CA 94080 false true false false Chief Fin. and Bus. Officer false Common Stock 2024-02-16 4 S false 5201 5.86 D 60755 D Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.61 to $6.15. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes 40,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,414 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 10, 2023. /s/ Jennifer Drimmer Rokovich, Attorney-in-Fact 2024-02-16